Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BET bromodomain inhibition potentiates radiosensitivity in models of H3K27-altered diffuse midline glioma

21 May 2024

Abstract excerpt

Diffuse midline glioma (DMG) H3K27-altered is one of the most malignant childhood cancers. Radiation therapy remains the only effective treatment yet provides a 5-year survival rate of only 1%. Several clinical trials have attempted to enhance radiation antitumor activity using radiosensitizing agents, although none have been successful. Given this, there is a critical need for identifying effective therapeutics...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromatin Remodeling and Cancer
Share to Glioma Diagnosis and Treatment
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38771655
DOI: 10.1172/jci174794

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BET bromodomain inhibition potentiates radiosensitivity in models of H3K27-altered diffuse midline gliomaPMID 38771655Read ↗

Radiotherapy and radio-sensitization in H3K27M -mutated diffuse midline gliomas.Semantic proximity Read ↗

H3K27M-driven hypertranscription leads to a new targetable dependency in diffuse midline gliomasSemantic proximity Read ↗

The genetic landscape of gliomas arising after therapeutic radiation.Semantic proximity Read ↗

Radiation-induced gliomas represent H3-/IDH-wild type pediatric gliomas with recurrent PDGFRA amplification and loss of CDKN2A/BSemantic proximity Read ↗

Disruption of ataxia telangiectasia-mutated kinase enhances radiation therapy efficacy in spatially directed diffuse midline glioma models.Semantic proximity Read ↗

The novel BET inhibitor UM-002 reduces glioblastoma cell proliferation and invasionSemantic proximity Read ↗

Bromodomain Inhibitor Review: Bromodomain and Extra-terminal Family Protein Inhibitors as a Potential New Therapy in Central Nervous System TumorsSemantic proximity Read ↗

H3K27M diffuse midline glioma is homologous recombination defective and sensitized to radiotherapy and NK cell-mediated antitumor immunity by PARP inhibitionSemantic proximity Read ↗

Radio-Resistance and DNA Repair in Pediatric Diffuse Midline GliomasSemantic proximity Read ↗

BET and Aurora Kinase A inhibitors synergize against MYCN-positive human glioblastoma cellsSemantic proximity Read ↗

Bench-to-bedside investigations of H3 K27-altered diffuse midline glioma: drug targets and potential pharmacotherapies.Semantic proximity Read ↗

Inhibition of H3K27M-enhanced ATM signaling increases radiation efficacy in diffuse midline gliomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.